Zeto's wireless EEG machine

News

Dry Electrode Headset EEG Receives FDA Approval for Clinical Use

In April 2018, the U.S. Food and Drug Administration (FDA) approved Zeto, Inc.’s “dry electrode” EEG (electroencephalogram) headset and its software platform for clinical use.

The Zeto headset, called zEEG, is easy to wear and does not need any preparation.

The EEG data collected from the headset is sent wirelessly to a cloud platform. This means the EEG is sent and stored using the internet.

The doctor or health care provider reading the EEG can view it live and read or interpret what the EEG means very quckily.

The dry electrode headset gives accurate 10-20 EEG placement and records EEG data consistent with the typical EEG.

“This approval is particularly meaningful to the Epilepsy Foundation, since the Zeto EEG system was selected as a prize winner in the 2016 Epilepsy Foundation Shark Tank. It was also awarded a New Therapy Commercialization Grant in 2017,” said Jacqueline French MD, chief scientific officer of the Epilepsy Foundation and professor of neurology, NYU Langone Health’s Comprehensive Epilepsy Center. “We saw a great potential for the EEG, an old diagnostic technique, to take a great leap into the modern age, making it more accessible for diagnosis of epilepsy.”

Source – https://www.epilepsy.com/learn/diagnosis/eeg/dry-electrode-headset-eeg

New Therapy Funding

The mission of the Epilepsy Therapy Project of the Epilepsy Foundation is to accelerate ideas into new therapies for people living with epilepsy and seizures.

Zeto is developing a turnkey solution for Routine EEG tests by providing EEG to facilities that do not have access to train EEG operators or neurologists. The goal of Zeto is to have a system that satisfies the following:

Source – https://www.epilepsy.com/make-difference/research-and-new-therapies/innovation/epilepsy-therapy-project/new-therapy-0

Shark Tank Competition 2016

The Epilepsy Foundation’s Shark Tank competition seeks to advance innovative ideas in epilepsy and seizure treatment and care. The winners will use their prize to accelerate their innovation to the next phase of development and closer to being accessible to people living with epilepsy.

In total, 65 individuals or teams entered the “Shark Tank” competition from across the U.S. and 13 countries around the world.

Source – https://www.epilepsy.com/make-difference/research-and-new-therapies/innovation/epilepsy-therapy-project/shark-tank-1